CRANBURY, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has appointed Andrew E. Mulberg, MD, FAAP, CPI as Vice President, Regulatory Strategy, effective today. He will be responsible for directing global regulatory strategies for all Amicus programs to bring multiple therapies to patients with rare and devastating diseases. Dr. Mulberg is a pediatric gastroenterologist who has spent the past 6 years working at the U.S. Food and Drug Administration (FDA), most recently as Deputy Director of the Division of Gastroenterology and Inborn Errors Products. Dr. Mulberg will serve as a member of the executive team reporting to Jay A. Barth, M.D., Chief Medical Officer.
“I am very pleased to welcome Andrew to our team,” stated Dr. Barth. “As we advance several programs through global clinical development, his direct experience at the FDA within the gastroenterology and inborn errors division, as well as his successful track record in drug development and regulatory approvals within industry, will be very valuable for Amicus. Andrew will be instrumental in shaping our regulatory strategies from investigational new drug, or IND, applications and first-in-man studies through regulatory approvals.”
In addition to Dr. Mulberg’s FDA experience, he previously held various roles of increasing responsibility within global drug development and medical affairs at leading pharmaceutical companies, including Johnson & Johnson, where he successfully led multiple products through clinical development to regulatory approvals.
Dr. Mulberg received his B.A. from Columbia University and his M.D. from the Mount Sinai School of Medicine. From 1993-2010, Andrew served as Attending Physician in Gastroenterology and Hepatology at Children’s Hospital of Philadelphia. He currently serves as Adjunct Professor of Pediatrics at the University of Maryland School of Medicine, Adjunct Associate Professor of Pediatrics in the University of Pennsylvania School of Medicine and Associate Professor of Pharmacy at the University of the Sciences in Philadelphia. He is also a member of numerous medical organizations including Alpha Omega Alpha Honor Medical Society, American Gastroenterological Association and the North American Society for Pediatric Gastroenterology and Nutrition.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease,Pompe disease, and other rare and devastating diseases.
